Development of vaccines for prevention of botulism

Biochimie

Volumn 82, Issue 9-10, 2000, Pages 955-966

  Byrne, Michael P ^a   Smith, Leonard A ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BOTULINUM TOXIN; BOTULINUM VACCINE; GENE PRODUCT; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

ANTIGEN FUNCTION; BIOSYNTHESIS; BOTULISM; CARBOXY TERMINAL SEQUENCE; DRUG EFFICACY; DRUG POTENCY; DRUG PURIFICATION; ENCEPHALITIS VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; GENE TECHNOLOGY; NONHUMAN; PICHIA PASTORIS; REVIEW; VACCINE PRODUCTION;

ANIMALIA; BACTERIA (MICROORGANISMS); CLOSTRIDIUM BOTULINUM; EQUIDAE; PICHIA PASTORIS; PRIMATES; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 0033748727     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(00)01173-1     Document Type: Review

References (75)

1. The most poisonous poison
2. Clostridial neurotoxins: Handling and action at the cellular and molecular level
3. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin
4. Molecular pharmacology of botulinum toxin and tetanus toxin
5. A common subunit structure in clostridium botulinum type A, B, and E toxins
6. The structure of botulinum neurotoxins
7. Mechanism of action of tetanus and botulinum neurotoxins
8. Bacterial protein toxins penetrate cells via a four-step mechanism
9. Neurospecific binding, internalization, and retrograde axonal transport
10. 125I-botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves
11. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes
12. Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity
13. Ganglioside-induced adherence of botulinum and tetanus neurotoxins to adducin
14. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides G(T1b)/G(D1a)
15. Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay
16. Cell surface receptors for protein toxins
17. 2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles
18. 125I-labelled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis
19. Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia
20. Identification of an ion channel-forming motif in the primary structure of tetanus and botulinum neurotoxins
21. Direct visualization of botulinum neurotoxin-induced channels in phospholipid vessicles
22. Membrane channel activity and translocation of botulinum and tetanus neurotoxins
23. Structure and function of Clostridium botulinum toxins
24. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E, J.
25. Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin
26. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc
27. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
28. Botulinum neurotoxin serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds
29. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins
30. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: Correlation with its blockade of catecholamine release
31. Clostridial neurotoxins: New tools for dissecting exocytosis
32. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC1/syntaxin
33. Clinical evaluation of botulinum toxoids
34. Studies of immunities to toxins of Clostridium botulinum. IX. Immunologic response of man to purified pentavalent ABCDE botulinum toxoid
35. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay
36. Clostridium botulinum type F: Isolation from venison jerky
37. Human botulism (type F) -- A rare type
38. Intestinal toxicoinfection by Clostridium botulinum type F in an adult. Case associated with Guillain-Barre syndrome
39. Toxoid of Clostridium botulinum type F: Purification and immunogenicity studies
40. The immunogenicity in humans of a botulinum type F vaccine
41. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins
42. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species
43. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
44. Analysis of the immune response to papain digestion products of tetanus toxin
45. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli
46. Development of recombinant vaccines for botulinum neurotoxin
47. The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene
48. Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen
49. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli
50. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum
51. Induction of an immune response by oral administration of recombinant botulinum toxin
52. Development of tier 1 neurobehavioral testing capabilities for incorporation into pivotal rodent safety assessment studies
53. Screening for neurotoxicity using a neurologically based examination and neuropathology
54. High-level expression and efficient assembly of hepatitis B surface antigen in the methylotrophic yeast, Pichia pastoris
55. High level expression of heterologous proteins in methylotrophic yeast Pichia pastoris
56. Foreign gene expression in yeast: A review
57. Recent advances in the expression of foreign genes in Pichia pastoris
58. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene
59. Expression of tetanus toxin fragment C in E. coli: High level expression by removing rare codons
60. Expression of tetanus toxin fragment C in yeast: Gene synthesis is required to elimate fortuitous polyadenylation sites in AT-rich DNA
61. Codon preferences in free-living microorganisms
62. Strategies for optimizing protein expression and secretion I the methylotrophic yeast Pichia pastoris
63. Structure of the receptor binding fragment H(C) of tetanus neurotoxin
64. Crystal structure of botulinum neurotoxin type A and implications for toxicity
65. Predicting differential antigen-antibody contact regions based on solvent accessibility
66. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin
67. Rapid selection using G418 of high copy number transformants of Pichia pastoris for high-level foreign gene expression
68. Expression, purification and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris
69. Pichia pastoris as a host system for transformations
70. Production and purification of heavy chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotropic yeast Pichia pastoris
71. Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment C of botulinum neurotoxin , serotype A
72. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate
73. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris
74. Efficacy of recombinant C fragment of heavy chain botulinum neurotoxin serotype B against lethal aerosol challenge of botulinum B toxin in rhesus monkeys